Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016

Elizabeth B. Gray, Ricardo M. La Hoz, Jaime S. Green, Holenarasipur R. Vikram, Theresa Benedict, Hilda Rivera, Susan P. Montgomery

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Heart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non-endemic countries. Methods: We present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule. Results: Of the 31 patients, 19 (61%) developed evidence of reactivation. Among the 19 patients, a majority (95%) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow-up (median: 60 weeks). Conclusions: Transplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.

Original languageEnglish (US)
Article numbere12996
JournalTransplant Infectious Disease
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Chagas Disease
Heart Transplantation
Chronic Disease
Latin America
Myocarditis
Cardiomyopathies
Immunosuppression
Allografts
Appointments and Schedules
Heart Failure
Transplant Recipients
Transplants
Polymerase Chain Reaction

Keywords

  • Chagas disease
  • heart transplant
  • reactivation
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

Gray, E. B., La Hoz, R. M., Green, J. S., Vikram, H. R., Benedict, T., Rivera, H., & Montgomery, S. P. (Accepted/In press). Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. Transplant Infectious Disease, [e12996]. https://doi.org/10.1111/tid.12996

Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. / Gray, Elizabeth B.; La Hoz, Ricardo M.; Green, Jaime S.; Vikram, Holenarasipur R.; Benedict, Theresa; Rivera, Hilda; Montgomery, Susan P.

In: Transplant Infectious Disease, 01.01.2018.

Research output: Contribution to journalArticle

Gray, Elizabeth B. ; La Hoz, Ricardo M. ; Green, Jaime S. ; Vikram, Holenarasipur R. ; Benedict, Theresa ; Rivera, Hilda ; Montgomery, Susan P. / Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. In: Transplant Infectious Disease. 2018.
@article{876674f40fda42368203694b52373091,
title = "Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016",
abstract = "Background: Heart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non-endemic countries. Methods: We present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule. Results: Of the 31 patients, 19 (61{\%}) developed evidence of reactivation. Among the 19 patients, a majority (95{\%}) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow-up (median: 60 weeks). Conclusions: Transplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.",
keywords = "Chagas disease, heart transplant, reactivation, Trypanosoma cruzi",
author = "Gray, {Elizabeth B.} and {La Hoz}, {Ricardo M.} and Green, {Jaime S.} and Vikram, {Holenarasipur R.} and Theresa Benedict and Hilda Rivera and Montgomery, {Susan P.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/tid.12996",
language = "English (US)",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016

AU - Gray, Elizabeth B.

AU - La Hoz, Ricardo M.

AU - Green, Jaime S.

AU - Vikram, Holenarasipur R.

AU - Benedict, Theresa

AU - Rivera, Hilda

AU - Montgomery, Susan P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Heart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non-endemic countries. Methods: We present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule. Results: Of the 31 patients, 19 (61%) developed evidence of reactivation. Among the 19 patients, a majority (95%) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow-up (median: 60 weeks). Conclusions: Transplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.

AB - Background: Heart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non-endemic countries. Methods: We present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule. Results: Of the 31 patients, 19 (61%) developed evidence of reactivation. Among the 19 patients, a majority (95%) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow-up (median: 60 weeks). Conclusions: Transplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.

KW - Chagas disease

KW - heart transplant

KW - reactivation

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=85054302525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054302525&partnerID=8YFLogxK

U2 - 10.1111/tid.12996

DO - 10.1111/tid.12996

M3 - Article

C2 - 30204269

AN - SCOPUS:85054302525

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

M1 - e12996

ER -